Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Trinity Biotech plc (ADR) (TRIB) An Unheralded Micro-Cap Stock Worth Owning?

Page 1 of 2

There are several ways to beat the market, and investing in small-cap stocks has historically been one of them. We like to improve our odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each year by hiring the best and the brightest to do research on stocks, including micro- and small-cap stocks that big brokerage houses simply don’t cover. Because of Carl Icahn and other elite funds’ exemplary historical records, we pay special attention to their picks in these unheralded stocks. In this article, we use hedge fund filing data to analyze Trinity Biotech plc (ADR) (NASDAQ:TRIB).

Trinity Biotech plc (ADR) (NASDAQ:TRIB) investors should be aware of an increase in support from the world’s most elite money managers lately. TRIB was in 20 hedge funds’ portfolios at the end of the third quarter of 2015. There were 19 hedge funds in our database with TRIB holdings at the end of the previous quarter. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as American Software, Inc. (NASDAQ:AMSWA), Blount International, Inc. (NYSE:BLT), and Navios Maritime Holdings Inc. (NYSE:NM) to gather more data points.

Follow Trinity Biotech Plc (NASDAQ:TRIB)
Trade (NASDAQ:TRIB) Now!

If you’d ask most traders, hedge funds are seen as unimportant, outdated investment tools of years past. While there are greater than 8,000 funds trading at present, we look at the masters of this group, approximately 700 funds. These investment experts have their hands on most of all hedge funds’ total asset base, and by watching their best equity investments, Insider Monkey has uncovered numerous investment strategies that have historically outpaced the broader indices. Insider Monkey’s small-cap hedge fund strategy exceeded the S&P 500 index by 12 percentage points annually for a decade in their back tests.

Now, we’re going to go over the new action encompassing Trinity Biotech plc (ADR) (NASDAQ:TRIB).

How have hedgies been trading Trinity Biotech plc (ADR) (NASDAQ:TRIB)?

At the end of the third quarter, a total of 20 of the hedge funds tracked by Insider Monkey held long positions in this stock, a 5% boost from the second quarter. With hedge funds’ positions undergoing their usual ebb and flow, there exists a few key hedge fund managers who were boosting their stakes substantially (or had already accumulated large positions).

When looking at the institutional investors followed by Insider Monkey, Richard S. Meisenberg’s ACK Asset Management has the number one position in Trinity Biotech plc (ADR) (NASDAQ:TRIB), worth close to $10.6 million, comprising 4.4% of its total 13F portfolio. The second-largest stake is held by Cardinal Capital, led by Amy Minella, holding a $9.7 million position; the fund has 0.6% of its 13F portfolio invested in the stock. Some other peers that are bullish contain Chuck Royce’s Royce & Associates, Richard Mashaal’s RIMA Senvest Management, and Peter S. Park’s Park West Asset Management.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!